Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam L Boxer

Showing results (141-150 of 300) with videos related to

Pageof 30
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|June 22, 2010
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS familyAdam L Boxer, Ian R Mackenzie, Bradley F Boeve, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 5, 2021
Uniform data set language measures for bvFTD and PPA diagnosis and monitoringAdam M Staffaroni, Sandra Weintraub, Katya Rascovsky, et al.
Nature Medicine|October 17, 2022
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trialTien Dam, Adam L Boxer, Lawrence I Golbe, et al.
Alzheimer'S Research & Therapy|August 29, 2024
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasiaBreton M Asken, Jessica M Bove, Russell M Bauer, et al.
Alzheimer'S Research & Therapy|September 22, 2023
Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairmentNidhi S Mundada, Julio C Rojas, Lawren Vandevrede, et al.
Journal of Alzheimer'S Disease : JAD|September 28, 2020
Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease StageBreton M Asken, Fanny M Elahi, Renaud La Joie, et al.
JAMA Neurology|April 26, 2016
Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal DegenerationMiguel A Santos-Santos, Maria Luisa Mandelli, Richard J Binney, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 26, 2025
Developing digital health technologies for frontotemporal degenerationNaomi Nevler, Debra Niehoff, Amanda M Gleixner, et al.
Journal of Alzheimer'S Disease : JAD|February 22, 2021
Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease StageBreton M Asken, Fanny M Elahi, Renaud La Joie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 15, 2024
Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementiasElena Tsoy, Renaud La Joie, Lawren VandeVrede, et al.
Pageof 30

Showing results (141-150 of 300) with videos related to

Sort By:
Pageof 30
Journal of Neurology, Neurosurgery, and Psychiatry|June 22, 2010
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS familyAdam L Boxer, Ian R Mackenzie, Bradley F Boeve, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|March 5, 2021
Uniform data set language measures for bvFTD and PPA diagnosis and monitoringAdam M Staffaroni, Sandra Weintraub, Katya Rascovsky, et al.
Nature Medicine|October 17, 2022
Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trialTien Dam, Adam L Boxer, Lawrence I Golbe, et al.
Alzheimer'S Research & Therapy|August 29, 2024
Clinical implications of head trauma in frontotemporal dementia and primary progressive aphasiaBreton M Asken, Jessica M Bove, Russell M Bauer, et al.
Alzheimer'S Research & Therapy|September 22, 2023
Head-to-head comparison between plasma p-tau217 and flortaucipir-PET in amyloid-positive patients with cognitive impairmentNidhi S Mundada, Julio C Rojas, Lawren Vandevrede, et al.
Journal of Alzheimer'S Disease : JAD|September 28, 2020
Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease StageBreton M Asken, Fanny M Elahi, Renaud La Joie, et al.
JAMA Neurology|April 26, 2016
Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal DegenerationMiguel A Santos-Santos, Maria Luisa Mandelli, Richard J Binney, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 26, 2025
Developing digital health technologies for frontotemporal degenerationNaomi Nevler, Debra Niehoff, Amanda M Gleixner, et al.
Journal of Alzheimer'S Disease : JAD|February 22, 2021
Plasma Glial Fibrillary Acidic Protein Levels Differ Along the Spectra of Amyloid Burden and Clinical Disease StageBreton M Asken, Fanny M Elahi, Renaud La Joie, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 15, 2024
Scalable plasma and digital cognitive markers for diagnosis and prognosis of Alzheimer's disease and related dementiasElena Tsoy, Renaud La Joie, Lawren VandeVrede, et al.
Pageof 30